New drug combo tested for Tough-to-Treat ovarian cancer
NCT ID NCT07370818
Summary
This study is testing a new drug combination (JPI-547 with bevacizumab) for ovarian cancer that has come back after previous treatments. It aims to see if this combination can help control the cancer longer and is safe for patients. The study is for people whose cancer responded to their most recent platinum chemotherapy but then returned while on or after a specific type of maintenance therapy (PARP inhibitor).
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Severance Hospital, Yonsei Cancer Center, Yonsei University College of Medicine
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.